Spring Bank

@SpringBankPharm

Spring Bank Pharmaceuticals (NASDAQ: SBPH) is a clinical-stage biopharma company developing a novel class of therapeutics using our SMNH chemistry platform.

Vrijeme pridruživanja: prosinac 2011.

Tweetovi

Blokirali ste korisnika/cu @SpringBankPharm

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @SpringBankPharm

  1. Prikvačeni tweet
    16. lis 2017.

    Learn about inarigivir (SB 9200), 's most advanced SMNH product candidate, & its novel method of action:

    Poništi
  2. 19. pro 2019.

    Designed to resemble naturally occurring nucleotides and nucleic acids in the body, our SMNH compounds cause no observed non-specific immune response and target a broad range of disease, including viral diseases and cancers. :

    Poništi
  3. 18. pro 2019.

    Developed for the treatment of , inarigivir is an orally-available selective immunomodulator that stimulates the innate immune response and inhibits viral replication. Watch this video to learn more :

    Poništi
  4. 17. pro 2019.

    Citing our two clinical programs, multiple data readouts, high quality partners and a cash runway beyond 2021, notes that Spring Bank could be undervalued. Read more. : FLS Disclaimer:

    Poništi
  5. 16. pro 2019.

    Inarigivir selectively activates within cells infected with , inhibiting viral replication and causing the induction of intracellular interferon signaling pathways for antiviral defense. Learn more about this mechanism here :

    Poništi
  6. 13. pro 2019.

    Among our pipeline of compounds, we plan to focus most on the inarigivir compound for treatment and SB 11285 for applications. See our full pipeline here. :

    Poništi
  7. 12. pro 2019.

    We design our proprietary SMNH compounds to bind specifically to their intended proteins, producing high therapeutic benefit over current therapies. We are committed to the highest standards of scientific excellence and integrity :

    Poništi
  8. 11. pro 2019.

    STimulator of INterferon Genes, or STING, is a protein that can activate the body’s innate immune system. SB 11285 is an agent that activates the STING pathway currently being developed for the treatment of some cancers. :

    Poništi
  9. 10. pro 2019.

    We released results from the first cohort of the clinical trial examining the co-administration of the low dose of inarigivir 50mg and the nucleoside analog, Vemlidy®. . Learn more about this trial here from :

    Poništi
  10. 9. pro 2019.

    Novel Small Molecule Drug Discovery Platform Harnesses Immune System to Defeat Cancers, Viral Infections & Inflammatory Diseases. Read the article from Dr. Kris Iyer in Drug Development & Delivery (FLS Disclaimer: ):

    Poništi
  11. 27. stu 2019.

    Designed to resemble naturally occurring nucleotides and nucleic acids in the body, our SMNH compounds are relatively easy to manufacture and include no observed non-specific immune response :

    Poništi
  12. 26. stu 2019.

    Inarigivir, our most advanced product candidate, has the potential to provide a functional cure for . Watch this video to learn more about inarigivir’s novel mechanism of action :

    Poništi
  13. 25. stu 2019.

    We are a clinical-stage company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid platform. Want more investment-relevant info? Check here :

    Poništi
  14. 22. stu 2019.

    Learn all about our development pipelines in our three main therapeutic areas: , , and inflammatory diseases :

    Poništi
  15. 21. stu 2019.

    At Spring Bank, we are committed to the highest standards of scientific excellence and integrity for the benefit of patients and the medical community. Learn more about our mission :

    Poništi
  16. 20. stu 2019.

    Our small molecule nucleic acid hybrid compounds act directly on target proteins, and have the potential to be used as part of combinatorial treatments, for example in with other antivirals :

    Poništi
  17. 18. stu 2019.

    Since inception, we have sought to apply our small molecule nucleic acid hybrid chemistry platform toward the discovery and development of novel drugs. The work has culminated in inarigivir, which is now being studied in Phase 2 clinical trials :

    Poništi
  18. 15. stu 2019.

    Want to dive deep into the science and documentation behind our technology? Take a look at our publications :

    Poništi
  19. 14. stu 2019.

    STimulator of INterferon Genes, or STING, is a protein that has the power to activate the body’s innate immune system. SB 11285 is a potent immunotherapeutic agent that activates the STING pathway. Read more about it here. :

    Poništi
  20. 13. stu 2019.

    We are focusing the development of our two most advanced product candidates, inarigivir and SB 11285, on the treatment of and various cancers respectively :

    Poništi
  21. 12. stu 2019.

    Did you know that attaining a functional cure for chronic will likely require modulation of the immune system? Our product candidate inarigivir is being developed with this in mind. Learn more about it :

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·